In subsequent in vivo experiments using a colon cancer mouse model, the administration of LPCAT2 or LD biogenesis inhibitors resulted in tumor regression and increased survival, indicating the significant improvement of LPCAT2-mediated drug resistance. This evidence concerns the gene LPCAT2 and colonic neoplasm.